Erudio Healtherudio.com
Sponsor
Amgen trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Amgen: DeLLphi-309. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 26 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Amgen). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| DeLLphi-309 NCT06745323 · Amgen | small cell lung cancer | Phase 2 | 206 | 39 | Standard | Oct 27, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| DeLLphi-305 NCT06211036 · Amgen DeepView → | first-line extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| CodeBreaK 200 NCT04303780 · Amgen DeepView → | previously treated KRAS G12C-mutated advanced NSCLC | Phase 3 | Deep | View | |||
| CodeBreaK 100 NCT03600883 · Amgen DeepView → | KRAS p.G12C-mutant advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| CodeBreaK 300 NCT05198934 · Amgen DeepView → | KRAS G12C-mutated chemorefractory metastatic colorectal cancer | Phase 3 | Deep | View | |||
| CANDOR NCT03158688 · Amgen DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| DeLLphi-301 NCT05060016 · Amgen DeepView → | relapsed/refractory small cell lung cancer | Phase 2 | Deep | View | |||
| DeLLphi-304 NCT05740566 · Amgen DeepView → | relapsed small cell lung cancer | Phase 3 | Deep | View | |||
| FORTITUDE-101 NCT05052801 · Amgen DeepView → | untreated advanced FGFR2b-overexpressing gastric or gastroesophageal junction cancer | Phase 3 | Deep | View | |||
| CodeBreaK 101 NCT04185883 · Amgen DeepView → | KRAS G12C-mutated advanced solid tumors | Phase 1 | Deep | View | |||
| DeLLphi-300 NCT03319940 · Amgen DeepView → | previously treated small cell lung cancer | Phase 1 | Deep | View | |||
| DeLLphi-312 NCT07005128 · Amgen DeepView → | first-line extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| VESALIUS-CV NCT03872401 · Amgen DeepView → | high cardiovascular risk without prior myocardial infarction/stroke | Phase 3 | Deep | View | |||
| DeLLphi-306 NCT06117774 · Amgen DeepView → | limited-stage small cell lung cancer | Phase 3 | Deep | View | |||
| FORTITUDE-102 NCT05111626 · Amgen DeepView → | FGFR2b-overexpressed untreated advanced gastric or gastroesophageal junction cancer | Phase 3 | Deep | View | |||
| DeLLpro-300 NCT04702737 · Amgen FocusedView → | de novo or treatment emergent neuroendocrine prostate cancer | Phase 1 | Focused | View | |||
| MTAPESTRY 101 NCT05094336 · Amgen FocusedView → | advanced MTAP-null solid tumors | Phase 1/Phase 2 | Focused | View | |||
| DeLLphi-303 NCT05361395 · Amgen FocusedView → | first-line extensive-stage small-cell lung cancer | Phase 1 | Focused | View | |||
| CodeBreaK 201 NCT04933695 · Amgen FocusedView → | first-line KRAS G12C-mutated stage IV NSCLC | Phase 2 | Focused | View | |||
| NCT04221542 NCT04221542 · Amgen FocusedView → | metastatic castration-resistant prostate cancer | Phase 1 | Focused | View | |||
| CHAMPION-1 NCT01677858 · Amgen FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| ParadigMM-1B NCT03287908 · Amgen FocusedView → | relapsed/refractory multiple myeloma | Phase 1 | Focused | View | |||
| XALience NCT07213674 · Amgen FocusedView → | chemotherapy-naïve metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| NCT01080391 NCT01080391 · Amgen FocusedView → | Not given | Phase 3 | Focused | View | |||
| AMG420 NCT03836053 · Amgen FocusedView → | Not given | Phase 1 | Focused | View | |||
| MTAPESTRY 103 NCT06360354 · Amgen FocusedView → | Not given | Phase 1 | Focused | View | |||
| XALute NCT06691984 · Amgen FocusedView → | metastatic castration-resistant prostate cancer previously treated with chemotherapy | Phase 3 | Focused | View | |||